Use of Aspirin and Initial Cardiovascular and Bleeding Risk in Patients with Chronic Kidney Disease

Overview

Journal Clin J Am Soc Nephrol

Specialty Nephrology

Date 2025 Jan 8

PMID 39774415

Authors

Jae Young Kim

Hyunsun Lim

Cheol Ho Park

Hyung Woo Kim

Tae Ik Chang

Seung Hyeok Han

Affiliations

Soon will be listed here.

References

Seong S, Kim Y, Khang Y, Park J, Kang H, Lee H . Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2016; 46(3):799-800. PMC: 5837262. DOI: 10.1093/ije/dyw253. View

Remuzzi G . Bleeding in renal failure. Lancet. 1988; 1(8596):1205-8. DOI: 10.1016/s0140-6736(88)92019-3. View

Zanoli L, Lentini P, Briet M, Castellino P, House A, London G . Arterial Stiffness in the Heart Disease of CKD. J Am Soc Nephrol. 2019; 30(6):918-928. PMC: 6551785. DOI: 10.1681/ASN.2019020117. View

Goicoechea M, de Vinuesa S, Quiroga B, Verde E, Bernis C, Morales E . Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). Cardiovasc Drugs Ther. 2018; 32(3):255-263. DOI: 10.1007/s10557-018-6802-1. View

Mann J, Joseph P, Gao P, Pais P, Tyrwhitt J, Xavier D . Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease. Kidney Int. 2022; 103(2):403-410. DOI: 10.1016/j.kint.2022.09.023. View

Baaten C, Schroer J, Floege J, Marx N, Jankowski J, Berger M . Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. Clin J Am Soc Nephrol. 2021; 17(1):155-170. PMC: 8763166. DOI: 10.2215/CJN.04100321. View

Seong S, Kim Y, Park S, Khang Y, Kim H, Park J . Cohort profile: the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in Korea. BMJ Open. 2017; 7(9):e016640. PMC: 5623538. DOI: 10.1136/bmjopen-2017-016640. View

Kendrick J, Chonchol M . Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008; 4(12):672-81. DOI: 10.1038/ncpneph0954. View

Palmer S, Di Micco L, Razavian M, Craig J, Perkovic V, Pellegrini F . Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012; 156(6):445-59. DOI: 10.7326/0003-4819-156-6-201203200-00007. View

10.

Gallagher H, Dumbleton J, Maishman T, Whitehead A, Moore M, Fuat A . Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of.... Trials. 2022; 23(1):331. PMC: 9021558. DOI: 10.1186/s13063-022-06132-z. View

11.

Goff Jr D, Lloyd-Jones D, Bennett G, Coady S, DAgostino Sr R, Gibbons R . 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 63(25 Pt B):2935-2959. PMC: 4700825. DOI: 10.1016/j.jacc.2013.11.005. View

12.

Wolfe R, Wetmore J, Woods R, McNeil J, Gallagher H, Roderick P . Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney Int. 2020; 99(2):466-474. PMC: 7957958. DOI: 10.1016/j.kint.2020.08.011. View

13.

McNeil J, Wolfe R, Woods R, Tonkin A, Donnan G, Nelson M . Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018; 379(16):1509-1518. PMC: 6289056. DOI: 10.1056/NEJMoa1805819. View

14.

Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Back M . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484. View

15.

Lee H, Lee H, Cho S, Kim D, Park S, Kim H . On-Treatment Blood Pressure and Cardiovascular Outcomes in Adults With Hypertension and Left Ventricular Hypertrophy. J Am Coll Cardiol. 2021; 78(15):1485-1495. DOI: 10.1016/j.jacc.2021.08.015. View

16.

Smith Jr S, Benjamin E, Bonow R, Braun L, Creager M, Franklin B . AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124(22):2458-73. DOI: 10.1161/CIR.0b013e318235eb4d. View

17.

Matsushita K, van der Velde M, Astor B, Woodward M, Levey A, de Jong P . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073-81. PMC: 3993088. DOI: 10.1016/S0140-6736(10)60674-5. View

18.

Davidson K, Barry M, Mangione C, Cabana M, Chelmow D, Coker T . Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2022; 327(16):1577-1584. DOI: 10.1001/jama.2022.4983. View

19.

McNeil J, Nelson M, Woods R, Lockery J, Wolfe R, Reid C . Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018; 379(16):1519-1528. PMC: 6433466. DOI: 10.1056/NEJMoa1803955. View

20.

Inker L, Eneanya N, Coresh J, Tighiouart H, Wang D, Sang Y . New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021; 385(19):1737-1749. PMC: 8822996. DOI: 10.1056/NEJMoa2102953. View